Hype and All That

The US Securities and Exchange Commission filed charges against the stem cell company CellCyte for "falsely telling investors that the company's cutting-edge stem cell technology had been proven successful and was headed for human trials." According to The Scientist, CellCyte licensed stem cell-delivery compounds in 2005 and said that organ repair trials in humans would start in 2008.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers find that historical factors influence which genes are the most highly studied, the Atlantic reports.

The US National Science Foundation's new sexual harassment policy is to go into effect next month, according to Nature News.

Researchers report using genotyping to tie together illegal ivory shipments and trace them back to a handful of cartels, the New York Times reports.

In Nature this week: genomic ancestry analysis of Sardinians, current noncoding mutations in colorectal cancer, and more.